APYX

Business Context and Reporting Period

Company: Apyx Medical Corporation
Filing Type: Form 8-K (Current Report)
Date: April 29, 2025
Context: The filing reports the publication of two peer-reviewed clinical studies evaluating the use of the Company's Renuvion^®

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance data.

Material Changes

No material financial changes versus a prior comparable period are reported in this document. The material event is the dissemination of new clinical data regarding the Renuvion^® system.

Outlook, Risks, and Management Commentary

• Management Commentary: The Company issued a press release (Exhibit 99.1) detailing the clinical studies. The studies support the use of Renuvion^® in specific body contouring applications.
• Risks and Contingencies: No specific risks or contingencies are detailed within the text of this 8-K filing.
• Guidance: No financial guidance or outlook is provided in this filing.

Investor Verification Checklist

• Review the attached press release (Exhibit 99.1) for specific details on the clinical study methodologies and outcomes.
• Verify the peer-reviewed status and publication venues of the two studies mentioned.
• Assess the potential commercial impact of lipoabdominoplasty applications on the Renuvion^® product line.
• Check for subsequent filings that may contain updated financial guidance based on this clinical news.